CENTESSA PHARMACEUTICA

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022

10 Nov 2022 07:00:04 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting 

03 Nov 2022 09:04:09 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

31 Oct 2022 08:00:02 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Poster Presentation Featuring Novel Orexin Receptor 2 (OX2R) Agonist Discovery Pipeline at the 26th Conference of the European Sleep Research Society (Sleep Europe 2022)

20 Sep 2022 08:34:08 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Orphan Drug Designation Granted to SerpinPC for the Treatment of Hemophilia B

14 Sep 2022 09:00:01 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index

12 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

29 Aug 2022 08:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874

10 Aug 2022 06:30:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs

25 Jul 2022 08:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors

01 Jul 2022 08:40:42 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

06 Jun 2022 08:00:02 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting

05 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

02 Jun 2022 06:29:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates

16 May 2022 07:00:01 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update

30 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day

23 Mar 2022 16:30:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise

07 Mar 2022 07:30:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease

24 Feb 2022 07:30:01 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease, Reports Initial Positive Safety Data from ALERT Study, and Announces Notice of Allowance for Key Lixivaptan U.S. Patent Application

14 Dec 2021 07:30:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Addition to NASDAQ Biotechnology Index

13 Dec 2021 16:15:00 By Nasdaq GlobeNewswire